IQVIA (NYSE:IQV) Upgraded to Strong-Buy at UBS Group

IQVIA (NYSE:IQV) was upgraded by research analysts at UBS Group to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

Several other analysts have also recently weighed in on the company. Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. Stifel Nicolaus raised their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $264.31.

IQVIA Price Performance

Shares of IQV opened at $269.95 on Wednesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company’s fifty day simple moving average is $253.09 and its 200 day simple moving average is $205.07. IQVIA has a 1-year low of $154.50 and a 1-year high of $277.40. The company has a market cap of $44.43 billion, a price-to-earnings ratio of 33.49, a PEG ratio of 2.30 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the company earned $2.81 earnings per share. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts forecast that IQVIA will post 11.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,581 shares of company stock worth $3,796,021 over the last 90 days. Insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. BlackRock Inc. bought a new stake in IQVIA during the second quarter valued at $2,811,292,000. Boston Partners raised its position in shares of IQVIA by 14.9% in the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after acquiring an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after acquiring an additional 528,753 shares in the last quarter. Cantillon Capital Management LLC lifted its stake in shares of IQVIA by 0.7% in the 4th quarter. Cantillon Capital Management LLC now owns 1,941,144 shares of the medical research company’s stock valued at $437,553,000 after purchasing an additional 14,210 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.